Condition category
Circulatory System
Date applied
23/01/2004
Date assigned
23/01/2004
Last edited
22/02/2008
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Prof John Cleland

ORCID ID

Contact details

Castle Hill Hospital
University of Hull
Cottingham
Kingston upon Hull
HU16 5UQ
United Kingdom
+44 (0)1482 624 083/084
J.G.Cleland@hull.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

D15

Study information

Scientific title

What is the most cost effective anti-thrombotic strategy to reduce mortality in heart failure? The WASH Study

Acronym

WASH Study

Study hypothesis

Heart failure is common and causes appreciable morbidity and mortality. It is associated with recurrent myocardial infarcts, strokes, and other thrombo-embolic events. For these reasons anti-thrombotic therapy using aspirin or warfarin is seen as normal clinical practice. However aspirin has a number of side-effects, and warfarin requires regular blood tests, increasing its cost and inconvenience for patients. Thus using these agents should be justified by clinical benefit. The aim of this study was to see if it would be possible to organise a trial of aspirin, warfarin, and no anti-thrombotic treatment.

Ethics approval

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Condition

Heart disease

Intervention

1. Aspirin
2. Wafarin
3. No anti-thrombotic treatment

Intervention type

Other

Phase

Not Specified

Drug names

Primary outcome measures

1. Deaths
2. Myocardial infarction
3. Stroke
4. Bleeding episodes
5. Dyspepsia
6. A number of laboratory tests

Secondary outcome measures

Not provided at time of registration

Overall trial start date

01/11/1995

Overall trial end date

30/09/1998

Reason abandoned

Eligibility

Participant inclusion criteria

Patients were being treated for heart failure, and had evidence of ventricular dysfunction to a defined level on echocardiography.

Participant type

Patient

Age group

Not Specified

Gender

Not Specified

Target number of participants

279

Participant exclusion criteria

Not provided at time of registration

Recruitment start date

01/11/1995

Recruitment end date

30/09/1998

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Castle Hill Hospital
Kingston upon Hull
HU16 5UQ
United Kingdom

Sponsor information

Organisation

Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)

Sponsor details

The Department of Health
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom

Sponsor type

Government

Website

http://www.doh.gov.uk

Funders

Funder type

Government

Funder name

NHS Cardiovascular Disease and Stroke National Research and Development Programme (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Results in http://www.ncbi.nlm.nih.gov/pubmed/15215806

Publication citations

  1. Results

    Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA, The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure., Am. Heart J., 2004, 148, 1, 157-164, doi: 10.1016/j.ahj.2004.03.010.

Additional files

Editorial Notes